After the large studies which set provisional stenting as the preferred strategy to treat bifurcations comes the double kissing crush technique (DK crush) to break the mold once again. This time, the DK crush technique is tested against provisional stenting in the left main, with a 3-year follow-up. The DKCRUSH-V, soon to be published in<a href="https://solaci.org/en/2019/10/17/the-era-of-provisional-stenting-for-bifurcations-comes-to-an-end/" title="Read more" >...</a>
The combination of coronary artery disease or peripheral vascular disease and a reason for anticoagulation, such as atrial fibrillation, results in many patients who receive antiplatelet therapy with aspirin plus anticoagulation with rivaroxaban, for example. It is a well-known fact that this combination (aspirin 100 mg per day plus rivaroxaban 2.5 mg twice per day) reduces cardiovascular<a href="https://solaci.org/en/2019/10/16/major-bleeding-in-patients-with-aspirin-plus-rivaroxaban-2/" title="Read more" >...</a>
The combination of coronary artery disease or peripheral vascular disease and a reason for anticoagulation, such as atrial fibrillation, results in many patients who receive antiplatelet therapy with aspirin plus anticoagulation with rivaroxaban, for example. It is a well-known fact that this combination (aspirin 100 mg per day plus rivaroxaban 2.5 mg twice per day) reduces cardiovascular<a href="https://solaci.org/en/2019/10/16/major-bleeding-in-patients-with-aspirin-plus-rivaroxaban/" title="Read more" >...</a>
Courtesy of SBHCI. Patients with severe aortic stenosis and low surgical risk showed decreased mortality, stroke, and heart failure hospitalization at one year with transcatheter aortic valve replacement compared with surgery. Improved quality of life may seem an obvious consequence, but until now that was mere speculation. This work, presented at the TCT 2019 Scientific Sessions<a href="https://solaci.org/en/2019/10/01/tct-2019-partner-3-obvious-short-term-quality-of-life-improvement-but-what-happens-afterwards/" title="Read more" >...</a>
Courtesy of SBHCI. Prognosis of patients with cardiac failure who develop secondary mitral regurgitation due to dilation is uncertain. The COAPT study was carried out in 78 centers across the US and Canada and included patients with moderate to severe mitral regurgitation (3 or 4 crossovers) symptomatic despite optimal medical treatment (OMT). 614 patients were<a href="https://solaci.org/en/2019/10/01/tct-2019-coapt-at-3-years-mitraclip-reached-functional-mitral-regurgitation-target/" title="Read more" >...</a>
Yesterday, Wednesday 25th September 2019, took place the session entitled The Best Intervention from Latin América at TCT 2019, one of the most relevant interventional cardiologist events in the world. In this occasion, before a packed room, prestigious Latin American professionals, most SOLACI members, discussed structural interventions, TAVR, MitraClip, CTO, complex cases, and plenty more. This<a href="https://solaci.org/en/2019/09/27/latin-american-session-at-tct-2019/" title="Read more" >...</a>
Myocardial revascularization surgery is still one of the most effective treatment strategies against coronary disease. One of the most important advantages of surgery over angioplasty is the chance to reach complete revascularization. This has proven to improve the survival of patients and to reduce the number of cardiovascular events. The choice of conduit for the<a href="https://solaci.org/en/2019/09/26/best-conduits-and-best-surgeons-for-the-best-outcome/" title="Read more" >...</a>
The fact that polymers can degrade after drug release seems interesting, more so when there appears to be evidence that they might cause inflammation (manly eosinophil infiltration) given its unwanted consequences. However, nice theories often get a reality check, and the polymer discussion is no exception. This article, soon to be published in J Am<a href="https://solaci.org/en/2019/09/25/do-polymers-play-any-role-in-drug-eluting-stents/" title="Read more" >...</a>
1-FDA Expands TAVR Indication to Low-Risk Patients Both the self-expandable valve Evolut R and its direct competitor, balloon-expandable valve Sapien 3, received the authorization to be indicated for low-risk patients in a long-awaited announcement made on August 16th, 2019. Read also HERE 2-Mechanisms of Post PCI Persistent Angina Angina persistence or recurrence after PCI can<a href="https://solaci.org/en/2019/09/16/the-most-read-articles-of-august-in-solaci-website/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Primary coronary angioplasty has been the treatment of choice for acute myocardial infarction (MI) for many years, but such strategy is associated with nonculprit lesions in a large group of patients. While it has been proven that nonculprit-lesion revascularization offers better outcomes, the groups that would benefit from it are<a href="https://solaci.org/en/2019/09/13/is-complete-revascularization-the-right-choice-in-acute-myocardial-infarction-with-multivessel-disease/" title="Read more" >...</a>